Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 108

1.

Late donor cardiectomy after paediatric heterotopic cardiac transplantation.

Tsang V, Yacoub M, Sridharan S, Burch M, Radley-Smith R, Khaghani A, Savoldo B, Amrolia PJ.

Lancet. 2009 Aug 1;374(9687):387-92. doi: 10.1016/S0140-6736(09)61201-0. Epub 2009 Jul 13.

PMID:
19604574
2.

Successful treatment with rituximab of lymphoproliferative disorder in a child after cardiac transplantation.

Herman J, Vandenberghe P, van den Heuvel I, Van Cleemput J, Winnepenninckx V, Van Damme-Lombaerts R.

J Heart Lung Transplant. 2002 Dec;21(12):1304-9.

PMID:
12490276
3.

Relationship of immunosuppression to Epstein-Barr viral load and lymphoproliferative disease in pediatric heart transplant patients.

Schubert S, Renner C, Hammer M, Abdul-Khaliq H, Lehmkuhl HB, Berger F, Hetzer R, Reinke P.

J Heart Lung Transplant. 2008 Jan;27(1):100-5. doi: 10.1016/j.healun.2007.09.027.

PMID:
18187094
4.

Post-transplantation lymphoproliferative disorder in heart and kidney transplant patients: a single-center experience.

Wasson S, Zafar MN, Best J, Reddy HK.

J Cardiovasc Pharmacol Ther. 2006 Mar;11(1):77-83.

PMID:
16703222
5.

Post-transplant lymphoproliferative disorder in pediatric heart transplant recipients.

Manlhiot C, Pollock-Barziv SM, Holmes C, Weitzman S, Allen U, Clarizia NA, Ngan BY, McCrindle BW, Dipchand AI.

J Heart Lung Transplant. 2010 Jun;29(6):648-57. doi: 10.1016/j.healun.2010.01.013. Epub 2010 Mar 20.

PMID:
20304682
6.

Adapted treatment of Epstein-Barr virus infection to prevent posttransplant lymphoproliferative disorder after heart transplantation.

Choquet S, Varnous S, Deback C, Golmard JL, Leblond V.

Am J Transplant. 2014 Apr;14(4):857-66. doi: 10.1111/ajt.12640. Epub 2014 Feb 19.

7.

Sustained Epstein-Barr virus detection in paediatric liver transplantation. Insights into the occurrence of late PTLD.

D'Antiga L, Del Rizzo M, Mengoli C, Cillo U, Guariso G, Zancan L.

Liver Transpl. 2007 Mar;13(3):343-8.

8.

Epstein-Barr virus--associated posttransplantation lymphoproliferative disorder with tacrolimus metabolism deterioration in infants after living-donor liver transplantation.

Fukushima D, Sato K, Kawagishi N, Ohuchi N, Satomi S.

Transplantation. 2015 Jan;99(1):114-9. doi: 10.1097/TP.0000000000000255.

PMID:
24846306
9.

Post-transplant lymphoproliferative disorder following pediatric heart transplantation.

Mendoza F, Kunitake H, Laks H, Odim J.

Pediatr Transplant. 2006 Feb;10(1):60-6.

PMID:
16499589
10.

Epstein-Barr virus-related disorders in children undergoing renal transplantation with tacrolimus-based immunosuppression.

Ellis D, Jaffe R, Green M, Janosky JJ, Lombardozzi-Lane S, Shapiro R, Scantlebury V, Vivas C, Jordan ML.

Transplantation. 1999 Oct 15;68(7):997-1003.

PMID:
10532541
11.

Successful treatment of a classic Hodgkin lymphoma-type post-transplant lymphoproliferative disorder with tailored chemotherapy and Epstein-Barr virus-specific cytotoxic T lymphocytes in a pediatric heart transplant recipient.

Basso S, Zecca M, Calafiore L, Rubert L, Fiocchi R, Paulli M, Quartuccio G, Guido I, Sebastiani R, Croci GA, Beschi C, Nardiello I, Ginevri F, Cugno C, Comoli P.

Pediatr Transplant. 2013 Nov;17(7):E168-73. doi: 10.1111/petr.12146. Epub 2013 Sep 1.

PMID:
23992468
12.

Low viral load post-transplant lymphoproliferative disease localized within the tongue.

Henry DD, Hunger SP, Braylan RC, Dharnidharka VR.

Transpl Infect Dis. 2008 Dec;10(6):426-30. doi: 10.1111/j.1399-3062.2008.00328.x. Epub 2008 Jul 22.

PMID:
18657087
13.

Rituximab therapy and reduction of immunosuppression to rescue graft function after renal posttransplantation lymphoproliferative disorder found by macrohematuria in a pancreas and kidney transplant recipient: a case report.

Miyagi S, Sekiguchi S, Kawagishi N, Akamatsu Y, Satoh K, Takeda I, Fukushima D, Kobayashi Y, Tokodai K, Fujimori K, Satomi S.

Transplant Proc. 2011 Nov;43(9):3299-301. doi: 10.1016/j.transproceed.2011.10.002.

PMID:
22099782
14.

Massive degeneration and atrophy of the native heart after heterotopic transplantation: a case report.

Fiorelli AI, Coelho GH, Lima JL, Lourenço DD, Gutierres P, Bacal F, Bocchi E, Dias RR, Stolf NA.

Transplant Proc. 2009 Apr;41(3):965-6. doi: 10.1016/j.transproceed.2009.02.012.

PMID:
19376400
15.

The role of quantitative Epstein-Barr virus polymerase chain reaction and preemptive immunosuppression reduction in pediatric liver transplantation: a preliminary experience.

Kogan-Liberman D, Burroughs M, Emre S, Moscona A, Shneider BL.

J Pediatr Gastroenterol Nutr. 2001 Oct;33(4):445-9.

PMID:
11698761
16.

Post-transplant lymphoproliferative disorders: improved outcome after clinico-pathologically tailored treatment.

Muti G, Cantoni S, Oreste P, Klersy C, Gini G, Rossi V, D'Avanzo G, Comoli P, Baldanti F, Montillo M, Nosari A, Morra E; Cooperative Study Group on PTLDs.

Haematologica. 2002 Jan;87(1):67-77.

17.

Epstein-Barr virus load in whole blood is associated with immunosuppression, but not with post-transplant lymphoproliferative disease in stable adult heart transplant patients.

Doesch AO, Konstandin M, Celik S, Kristen A, Frankenstein L, Sack FU, Schnabel P, Schnitzler P, Katus HA, Dengler TJ.

Transpl Int. 2008 Oct;21(10):963-71. doi: 10.1111/j.1432-2277.2008.00709.x. Epub 2008 Jun 24.

18.

Diagnosis and treatment of post-transplantation lymphoproliferative disorder in pediatric heart transplant patients.

Schubert S, Abdul-Khaliq H, Lehmkuhl HB, Yegitbasi M, Reinke P, Kebelmann-Betzig C, Hauptmann K, Gross-Wieltsch U, Hetzer R, Berger F.

Pediatr Transplant. 2009 Feb;13(1):54-62. doi: 10.1111/j.1399-3046.2008.00969.x. Epub 2008 Jun 1.

PMID:
18518912
19.
20.

Tumor origin and CD20 expression in posttransplant lymphoproliferative disorder occurring in solid organ transplant recipients: implications for immune-based therapy.

Gulley ML, Swinnen LJ, Plaisance KT Jr, Schnell C, Grogan TM, Schneider BG; Southwest Oncology Group.

Transplantation. 2003 Sep 27;76(6):959-64.

PMID:
14508361
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk